EASEE4YOU: EASEE® Neurostimulation for Adolescents Aged 12–17 with Drug-Resistant Focal Epilepsy
First Clinical Trial of the EASEE® System in Adolescents
The ongoing study in adolescents aged 12 to 17 years aims to further expands the evidence base on the safety and efficacy of the EASEE® System in drug-resistant focal epilepsy.
Unmet Need
Many adolescents with focal epilepsy fail to achieve adequate seizure control despite medication.
Innovative Treatment Approach
The EASEE® System uses transcranial focal cortex stimulation and is being studied in adolescents aged 12 to 17 for the first time.
Clinical Evidence
The study aims to provide important data on safety and efficacy and expand the evidence base for EASEE®.
The Study at a Glance
- Indication: Drug-resistant focal epilepsy
- Population: 35 adolescents aged 12 – 17
- Intervention: EASEE® System
- Study Design: International, multi-center, prospective study
- Objective: Evaluation of the safety and efficacy of the treatment
Study Overview
Enrollment
Baseline
Implantation
Activation
Follow-up
Study End
Want to learn more about the EASEE4YOU Study?
For further details on the study design, eligibility criteria, and study centers, please see the official study registry entry.
The experts behind EASEE4YOU
Prof. Dr. med. Steffen Syrbe
Head of Pediatric Epileptology at Heidelberg University Hospital
Prof. Dr. med. Volker Arnd Coenen
Medical Director of the Department of Stereotactic and Functional Neurosurgery at Freiburg University Hospital
Interested in EASEE4YOU?
Our study team is happy to answer any questions you may have about EASEE4YOU.
